Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children

7 hours ago 2
View of Novartis innovative medicines company office building with logo sign, pharmaceutical corporation

Veronique D

  • Novartis (NYSE:NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants.
  • The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for

Recommended For You

More Trending News

Read Entire Article